The U.S. Food and Drug Administration (FDA) approved a supplemental application for Opdivo (nivolumab) on September 22, 2017. This approval, designated as a Class: Efficacy application, was sponsored by Bristol Myers Squibb, indicating an expansion of the drug's demonstrated effectiveness.
Background
Nivolumab is an established immunotherapy drug. Supplemental applications for efficacy are submitted to the FDA when new clinical data demonstrate that an already approved drug is effective for a new indication, a different patient population, or a modified dosing regimen. Such approvals are based on rigorous review of clinical trial data that confirm the drug's benefits outweigh its risks in the expanded context. This process ensures that new uses for medications are thoroughly vetted before they are made available to patients and healthcare providers.
What this means
This supplemental approval for Opdivo (nivolumab) signifies that the FDA has reviewed and accepted new clinical evidence supporting the drug's efficacy for an expanded use. For clinicians, this means Opdivo is now approved for an additional indication or patient population, or under different conditions of use, providing more treatment options for patients. This regulatory milestone reflects the ongoing research and development efforts to broaden the utility of established therapies. Researchers will find this approval relevant as it incorporates new clinical data into the drug's official labeling, potentially guiding future studies and treatment paradigms. Patient advocates can highlight this as an expansion of available therapeutic options.
Source
The information regarding this supplemental approval was obtained from the U.S. Food and Drug Administration (FDA) website. The approval for BLA 125554 S-41 was posted on September 22, 2017, on accessdata.fda.gov.